361 related articles for article (PubMed ID: 16014931)
1. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
4. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.
Barratt-Boyes SM; Soloff AC; Gao W; Nwanegbo E; Liu X; Rajakumar PA; Brown KN; Robbins PD; Murphey-Corb M; Day RD; Gambotto A
J Gen Virol; 2006 Jan; 87(Pt 1):139-149. PubMed ID: 16361426
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
6. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
Fuchs JD; Bart PA; Frahm N; Morgan C; Gilbert PB; Kochar N; DeRosa SC; Tomaras GD; Wagner TM; Baden LR; Koblin BA; Rouphael NG; Kalams SA; Keefer MC; Goepfert PA; Sobieszczyk ME; Mayer KH; Swann E; Liao HX; Haynes BF; Graham BS; McElrath MJ;
J AIDS Clin Res; 2015 May; 6(5):. PubMed ID: 26587311
[TBL] [Abstract][Full Text] [Related]
10. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
12. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.
Tan WG; Jin HT; West EE; Penaloza-MacMaster P; Wieland A; Zilliox MJ; McElrath MJ; Barouch DH; Ahmed R
J Virol; 2013 Feb; 87(3):1359-72. PubMed ID: 23175355
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
[TBL] [Abstract][Full Text] [Related]
15. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
16. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
Bolton DL; Santra S; Swett-Tapia C; Custers J; Song K; Balachandran H; Mach L; Naim H; Kozlowski PA; Lifton M; Goudsmit J; Letvin N; Roederer M; Radošević K
Vaccine; 2012 Sep; 30(41):5991-8. PubMed ID: 22732429
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
18. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
[TBL] [Abstract][Full Text] [Related]
19. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
Santra S; Seaman MS; Xu L; Barouch DH; Lord CI; Lifton MA; Gorgone DA; Beaudry KR; Svehla K; Welcher B; Chakrabarti BK; Huang Y; Yang ZY; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2005 May; 79(10):6516-22. PubMed ID: 15858035
[TBL] [Abstract][Full Text] [Related]
20. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]